ArticleJournal of lipid research2026
Development and application of a fluorescent immunochromatographic assay for metabolite G-DCA quantification in ICP.
Article in Journal of lipid research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy-specific liver disorder characterized by dysregulated bile acid metabolism, which can lead to severe adverse pregnancy outcomes. Glycine-conjugated deoxycholic acid (G-DCA) is a small-molecule metabolite that has been reported to be elevated in the serum of patients with ICP; however, its clinical application remains limited because conventional chromatographic methods for its quantification are time-consuming, costly, and not well-suited for rapid clinical screening. To address this gap, we developed a time-resolved fluorescence immunochromatographic test strip (TRF-ICTS) for the quantitative detection of serum G-DCA. Based on a small-molecule competitive binding design, the assay requires only 10 μl of serum sample and enables rapid detection within 16 min. The TRF-ICTS demonstrated good analytical performance, with a linear range of 0.05-10.0 ng/ml and a detection limit of 0.074 ng/ml, and maintained stable performance over two weeks of storage at both 4°C and 37°C. The results showed good quantitative agreement with LC-MS/MS measurements. Evaluation of sensitivity, specificity, and precision demonstrated that all parameters were within acceptable ranges. Clinical validation using serum samples from ICP patients and healthy pregnant women showed that G-DCA levels were elevated across different trimesters and were more pronounced in patients with severe ICP and adverse pregnancy outcomes. Overall, the developed TRF-ICTS provides a rapid and sensitive method for quantifying G-DCA, which may serve as a complementary biomarker for ICP diagnosis and disease stratification, providing additional insights into bile acid changes following UDCA treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.